Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes

Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin

(2016) Emilie Bahne et al.   DIABETES OBESITY & METABOLISM

Metformin and the gastrointestinal tract

(2016) Laura J. McCreight et al.   DIABETOLOGIA

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

(2016) Robert A. Scott et al.   Science Translational Medicine

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

(2015) Jennifer B. Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

(2015) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis

(2015) Jessica E. Potts et al.   PLoS One

Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: Stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?

(2014) Tongzhi Wu et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium

(2014) Robert W. Koivula et al.   DIABETOLOGIA

Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and "Isoglycemic" Intravenous Glucose

(2013) I. Vardarli et al.   DIABETES

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes

(2013) Carolina Solis-Herrera et al.   DIABETES CARE

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial

(2013) David Preiss et al.   Lancet Diabetes & Endocrinology

Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study

(2012)   DIABETES CARE

Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus

(2012) S. K. Thondam et al.   DIABETIC MEDICINE

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Mechanisms Underlying Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal L Cell

(2011) Andrew J. Mulherin et al.   ENDOCRINOLOGY

Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1

(2010) E M Migoya et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

(2010) A. Maida et al.   DIABETOLOGIA

Addition of metformin to exogenous glucagon-like peptide–1 results in increased serum glucagon-like peptide–1 concentrations and greater glucose lowering in type 2 diabetes mellitus

(2010) Joy Cuthbertson et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin

(2009) Pernille Fog Svendsen et al.   METABOLISM-CLINICAL AND EXPERIMENTAL